Nalaganje...
Development of Sunitinib in Hepatocellular Carcinoma: Rationale, Early Clinical Experience, and Correlative Studies
The approval of a multitargeted receptor tyrosine kinase inhibitor, sorafenib, with activity against vascular endothelial growth factor receptor-2 and -3, Raf-1 and B-Raf, platelet-derived growth factor receptor-α and -β, and other kinases, has ushered in the era of molecular targeted agents in adva...
Shranjeno v:
| izdano v: | Cancer J |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2009
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4792519/ https://ncbi.nlm.nih.gov/pubmed/19672141 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PPO.0b013e3181af5e35 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|